Recovery questions, clearly framed
A careful guide to CoreAge Rx’s BPC-157 Black Friday advertising, focused on describing a recovery concern, understanding evidence limits and checking how the advertised preparation and plan would be assessed.
Explore the detailsA closer look
A recovery concern deserves a clear conversation even when a seasonal offer is what first catches your attention. The Fieldbook helps you describe the question you want answered and separate it from a campaign’s language about repair. It does not turn an injury, symptom or training goal into a recommendation for BPC-157.
This is promotional coverage of CoreAge Rx, based on pages checked November 7, 2026. Its BPC-157 Black Friday campaign is live, while the general product page says Coming soon. We have not completed enrollment or assessed a patient. Confirm current access with the provider and discuss suitability with the treating clinician.
Take this with you
What should be assessed about the concern that brought me here?
Which evidence is relevant to the proposed BPC-157 use and route?
Can the provider identify the exact preparation and current enrollment path?
What would the approved order require financially at the start and renewal?
Sponsored · CoreAge Rx
Prices below are advertised by CoreAge Rx. Confirm eligibility, current terms, and total charges with the provider before enrolling.
Advertised Black Friday terms
$597 billed upfront for six months
Advertised through November 27, 2026, at 11:59 p.m. Eastern. Confirm current checkout, cancellation and renewal terms.
Compounded and not FDA-approved. Human evidence is limited; discuss risks and suitability with a licensed clinician.
Provider sourcePromotional placement. This publication is part of a commonly owned promotional network supporting CoreAge Rx. Placement is not an independent ranking or a claim that treatment is appropriate for you. How this site works.
Other companies · checked November 8, 2026
A useful comparison entry needs more than BPC-157 in its title. The other-company review checked clinic listings and holiday terms while excluding research-only products. Neither a nearby Black Friday banner nor another product’s discount establishes a promotion for the preparation this fieldbook concerns.
CoreAge Rx remains the disclosed promotional placement. Any future comparison must identify the preparation and terms; no offer would establish suitability or FDA approval of compounded medicine.
No matching competitor patient-care BPC-157 offer was verified on November 8. This is the limit of the checked evidence, not a claim that none could be announced.
Selected offers checked against providers’ own pages on November 8, 2026. These are advertised terms; checkout, stock and individual eligibility were not tested. CoreAge Rx sponsorship remains separately disclosed.
The reading room
Prepare a useful clinical discussion by recording the question that brought you to BPC-157 advertising, while leaving diagnosis and treatment selection to the clinician.
Read the campaign, product listing and FDA context as different kinds of information, each with a limited role in understanding the advertised BPC-157 plan.
Before you decide
No. This guide does not adopt the provider’s repair or recovery descriptions as proven outcomes. FDA identifies limited safety information and possible immunogenicity, impurity and characterization concerns. Ask a clinician to assess the concern and explain relevant evidence.
CoreAge Rx advertises $597 upfront for six months of BPC-157, equivalent to $99.50 per month. Its stated comparison is $1,194. These are provider-advertised terms, and the actual order, availability and prescribing decision still need confirmation.
No. The separate BPC-157 product listing displays Coming soon. We have verified the advertising page, not a successful intake, prescription or delivery. Ask CoreAge Rx which current route applies to the preparation and your state before relying on the offer.
A specific question gives the clinician room to assess the concern and explain relevant options. You can identify the BPC-157 campaign you read without deciding the outcome in advance. This site cannot determine what treatment, if any, is appropriate.